MX2019003229A - Formulaciones liquidas estables. - Google Patents

Formulaciones liquidas estables.

Info

Publication number
MX2019003229A
MX2019003229A MX2019003229A MX2019003229A MX2019003229A MX 2019003229 A MX2019003229 A MX 2019003229A MX 2019003229 A MX2019003229 A MX 2019003229A MX 2019003229 A MX2019003229 A MX 2019003229A MX 2019003229 A MX2019003229 A MX 2019003229A
Authority
MX
Mexico
Prior art keywords
liquid formulations
stable liquid
oily carrier
triglyceride
proportion
Prior art date
Application number
MX2019003229A
Other languages
English (en)
Inventor
Arthur Sherry Robert
Gerard Barfield John
Sam Tang Weng
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of MX2019003229A publication Critical patent/MX2019003229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con la invención actual, se proporciona una formulación líquida para administración oral que comprende un ingrediente farmacéutico activo dispersado en un portador aceitoso farmacéuticamente aceptable, el portador aceitoso comprende una proporción mayor de un aceite basado en triglicérido y una proporción mejor de un compuesto ceroso.
MX2019003229A 2016-09-23 2017-09-22 Formulaciones liquidas estables. MX2019003229A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16020346.9A EP3299017A1 (en) 2016-09-23 2016-09-23 Formulation
PCT/EP2017/025268 WO2018054552A1 (en) 2016-09-23 2017-09-22 Stable liquid formulations

Publications (1)

Publication Number Publication Date
MX2019003229A true MX2019003229A (es) 2019-09-13

Family

ID=57003306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003229A MX2019003229A (es) 2016-09-23 2017-09-22 Formulaciones liquidas estables.

Country Status (5)

Country Link
US (1) US20190247308A1 (es)
EP (2) EP3299017A1 (es)
CN (1) CN109862894A (es)
MX (1) MX2019003229A (es)
WO (1) WO2018054552A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
EP3057571B1 (en) * 2013-10-18 2019-03-06 Norbrook Laboratories Limited Proton pump inhibitor paste compositions

Also Published As

Publication number Publication date
EP3515440A1 (en) 2019-07-31
CN109862894A (zh) 2019-06-07
WO2018054552A1 (en) 2018-03-29
US20190247308A1 (en) 2019-08-15
EP3299017A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
MX2021006035A (es) Formulaciones cannabinoides estables.
WO2018022815A3 (en) Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2020000747A1 (es) Formulaciones de niraparib.
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
MX2017013141A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2019003229A (es) Formulaciones liquidas estables.
PH12019500024A1 (en) Pharmaceutical compositions
CO7310521A2 (es) Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo
PH12020551547A1 (en) Pharmaceutical preparation
MX2020005921A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
TR201815617A2 (tr) Deksketoprofen içeren bir formülasyon.
MX2020006886A (es) Sistema para suministro de medicamento.
MX2013008994A (es) Composicion solida estable de inmunosupresores.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
UA111462C2 (uk) Застосування (s)-2,6-діаміногексанової кислоти 3-метил-1,2,4-триазоліл-5-тіоацетату як активної основи лікарських засобів для профілактики та лікування порушень життєзабезпечуючих функцій цнс при важких формах гострого отруєння етанолом